{"title":"Pre- and posttransplant use of mogamulizumab in patients with aggressive adult T-cell leukemia-lymphoma: A statement from key opinion leaders in Japan","authors":"Shigeo Fuji, Koji Kato, Nobuaki Nakano, Takashi Ishida, Kenji Ishitsuka, Ilseung Choi, Ken-ichi Matsuoka, Atae Utsunomiya","doi":"10.1002/acg2.5","DOIUrl":null,"url":null,"abstract":"<p>Recently, the anti-CCR4 antibody mogamulizumab (Moga, Kyowa Hakko Kirin Co., Ltd, Tokyo, Japan) was approved as a treatment for CCR4-positive adult T-cell leukemia-lymphoma (ATL) in Japan. We use Moga before or after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with aggressive ATL. A recent retrospective analysis using a database from a nationwide survey showed that the use of Moga before allo-HSCT was associated with an increased risk of severe/steroid-refractory acute GVHD and inferior overall survival. Meanwhile, it was reported that a number of patients with chemotherapy-refractory ATL achieved disease control with Moga, including those who subsequently underwent allo-HSCT. To address these issues pertaining to Moga in transplant-eligible patients with ATL, a key opinion leader (KOL) meeting comprising hematologists and transplant physicians was conducted by Kyowa Hakko Kirin Co., Ltd. in Japan. The goal of this KOL meeting was to design a framework to guide decision-making on the use of Moga in transplant-eligible patients with ATL. KOLs first presented their experiences, and after a subsequent discussion, the KOLs agreed on the key scientific statement as summarized in this Expert Commentary. Our experiences suggest that a good number of patients benefited from Moga, achieving disease control that was often unattainable by conventional chemotherapies. However, as our statement is based largely on retrospective studies and real clinical practice, it requires further validation. Nevertheless, we believe that this statement should help efficiently guide decision-making concerning Moga use in transplant-eligible patients with ATL.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.5","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cell and gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acg2.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
Recently, the anti-CCR4 antibody mogamulizumab (Moga, Kyowa Hakko Kirin Co., Ltd, Tokyo, Japan) was approved as a treatment for CCR4-positive adult T-cell leukemia-lymphoma (ATL) in Japan. We use Moga before or after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with aggressive ATL. A recent retrospective analysis using a database from a nationwide survey showed that the use of Moga before allo-HSCT was associated with an increased risk of severe/steroid-refractory acute GVHD and inferior overall survival. Meanwhile, it was reported that a number of patients with chemotherapy-refractory ATL achieved disease control with Moga, including those who subsequently underwent allo-HSCT. To address these issues pertaining to Moga in transplant-eligible patients with ATL, a key opinion leader (KOL) meeting comprising hematologists and transplant physicians was conducted by Kyowa Hakko Kirin Co., Ltd. in Japan. The goal of this KOL meeting was to design a framework to guide decision-making on the use of Moga in transplant-eligible patients with ATL. KOLs first presented their experiences, and after a subsequent discussion, the KOLs agreed on the key scientific statement as summarized in this Expert Commentary. Our experiences suggest that a good number of patients benefited from Moga, achieving disease control that was often unattainable by conventional chemotherapies. However, as our statement is based largely on retrospective studies and real clinical practice, it requires further validation. Nevertheless, we believe that this statement should help efficiently guide decision-making concerning Moga use in transplant-eligible patients with ATL.
最近,抗CCR4抗体mogamulizumab(Moga,Kyowa Hakko Kirin Co.,Ltd,Tokyo,Japan)在日本被批准作为CCR4阳性成人T细胞白血病淋巴瘤(ATL)的治疗药物。我们在侵袭性ATL患者异基因造血干细胞移植(allo-HSCT)前后使用Moga。最近一项使用全国性调查数据库的回顾性分析显示,在异基因造血干细胞移植前使用Moga与严重/类固醇难治性急性移植物抗宿主病的风险增加和总体生存率下降有关。同时,据报道,许多化疗难治性ATL患者通过Moga实现了疾病控制,包括那些随后接受allo-HSCT的患者。为了解决符合移植条件的ATL患者中与Moga有关的这些问题,日本有限公司Kyowa Hakko Kirin Co.,Ltd.举办了一次由血液学家和移植医生组成的关键意见领袖(KOL)会议。本次KOL会议的目标是设计一个框架,指导符合移植条件的ATL患者使用Moga的决策。KOL首先介绍了他们的经验,经过随后的讨论,KOL同意了本专家评论中总结的关键科学声明。我们的经验表明,大量患者受益于Moga,实现了传统化疗无法实现的疾病控制。然而,由于我们的声明主要基于回顾性研究和实际临床实践,因此需要进一步验证。尽管如此,我们认为这一声明应有助于有效指导符合移植条件的ATL患者使用Moga的决策。